Bio-Techne TECH Ratios & Valuation
| TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 65%-0.8pp | 65.2%-0.4pp | 65.4%-0.1pp | 64.8%-1.6pp | 65.8%-1.0pp | |
| Free cash flow margin | 22.3%+4.0pp | 18.3%-2.9pp | 18.4%-2.5pp | 21%+0.7pp | 18.3%-3.5pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | |
| Inventory turnover | 2.2×-0.1× | 2.1×-0.1× | 2.2×0.0× | 2.3×+0.1× | 2.2×0.0× | |
| Liquidity | ||||||
| Current ratio | 4.5×+0.8× | 4.5×+0.6× | 4.2×-0.3× | 3.5×-0.4× | 3.7×-0.4× | |
| Quick ratio | 3.2×+0.6× | 3.1×+0.3× | 2.8×-0.5× | 2.4×-0.4× | 2.6×-0.3× | |
| Cash ratio | 1.4×+0.5× | 1.2×+0.1× | 1×-0.3× | 0.9×0.0× | 0.8×-0.1× | |
| Leverage | ||||||
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Valuation | ||||||
| Market capitalization | $8.18B-11.8% | $9.16B-19.9% | $8.66B-31.4% | $7.84B-30.5% | $9.27B-16.3% | |
| Enterprise value | $8.26B-13.6% | $9.34B-19.9% | $8.91B-30.5% | $8.12B-29.6% | $9.55B-16.4% | |
| Price / sales | 6.8×-0.9× | 7.5×-2.0× | 7.1×-3.7× | 6.4×-3.3× | 7.7×-1.9× | |
| EV / sales | 6.8×-1.1× | 7.7×-2.1× | 7.3×-3.6× | 6.7×-3.3× | 7.9×-2.0× | |
| Free cash flow yield | 3.3%+0.9pp | 2.4%+0.2pp | 2.6%+0.6pp | 3.3%+1.2pp | 2.4%+0.1pp | |
| Dividend yield | 0.6%+0.1pp | 0.5%+0.1pp | 0.6%+0.2pp | 0.6%+0.2pp | 0.5%+0.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Bio-Techne's profit margins?
- Bio-Techne (TECH) runs a 65.0% gross margin and a 14.2% operating margin, with a 10.9% net margin.
- Where do Bio-Techne's ratios come from?
- Every ratio is computed from Bio-Techne's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
